Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group

Blood
Children's Oncology GroupStella M Davies

Abstract

We evaluated differences in outcome by ethnicity among children with acute myeloid leukemia (AML). We analyzed 791 children in the CCG 2891 trial and confirmed positive findings in 850 children in the CCG 2961 trial. Hispanic and black children treated with chemotherapy in CCG 2891 had significantly inferior overall survival (OS) from study entry compared with white children (37%+/- 9% vs 48%+/- 4% [P = .016] and 34% +/- 10% vs 48% +/- 4%, [P = .007], respectively). Significantly fewer black children had related donors. Analyses of CCG 2961 confirmed that black children had significantly decreased OS rates compared with white children (45% +/- 12% vs 60% +/- 4%; P = .007) The difference in OS rates between Hispanic and white children approached statistical significance (51% +/- 8% vs 60% +/- 4%; P = .065) Only 7.5% of black children on CCG 2961 had an available family donor. In conclusion, Hispanic and black children with AML have worse survival than white children. Access to chemotherapy, differences in supportive care or leukemia phenotype, and reduced compliance are unlikely explanations for this difference because therapy was given intravenously according to CCG protocols. Fewer black children than expected had an available...Continue Reading

References

Jul 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M MitchellK A Schulman
Feb 24, 2001·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·J H LaverM R Abboud
Jan 30, 2003·American Journal of Hematology·Ronny AlcalaiOra Paltiel
Mar 21, 2003·The New England Journal of Medicine·Richard S CooperRyk Ward
Mar 21, 2003·The New England Journal of Medicine·Esteban González BurchardNeil Risch
Jun 20, 2003·The New England Journal of Medicine·Scott M Williams, Alan R Templeton
Oct 3, 2003·Current Oncology Reports·Soheil MeshinchiRobert J Arceci
Oct 16, 2003·JAMA : the Journal of the American Medical Association·Nina S Kadan-LottickJames G Gurney
Feb 21, 2004·Blood·Mikkael A SekeresUNKNOWN Cancer and Leukemia Group B
Jan 13, 2005·JAMA : the Journal of the American Medical Association·Beverly J LangeTodd A Alonzo

❮ Previous
Next ❯

Citations

Sep 14, 2012·Cancer Causes & Control : CCC·M I PatelK F Rhoads
Sep 17, 2013·Cancer Causes & Control : CCC·Patricia C ValeryJoanne F Aitken
May 29, 2008·Current Treatment Options in Oncology·Jeffrey E Rubnitz
Jul 24, 2010·Current Hematologic Malignancy Reports·Mohamed RadhiAlan Gamis
Oct 28, 2009·The Pediatric Infectious Disease Journal·Brian T FisherTheoklis E Zaoutis
Oct 29, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John T HoranUNKNOWN Children's Oncology Group
Nov 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tara O HendersonSusan L Cohn
May 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ching-Hon PuiAmar Gajjar
May 2, 2013·Haematologica·Christian Michel Zwaan, Richard Sposto
Dec 25, 2013·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Shannon L MaudeRichard Aplenc
Sep 21, 2011·Expert Review of Anticancer Therapy·Carmelo RizzariValentino Conter
Feb 2, 2010·Hematology/oncology Clinics of North America·Jeffrey E RubnitzFranklin O Smith
Feb 5, 2008·Pediatric Clinics of North America·Jeffrey E RubnitzFranklin O Smith
May 24, 2012·Pediatric Blood & Cancer·Wasil JastaniahTaha M Khattab
Feb 18, 2011·Pediatric Blood & Cancer·Smita Bhatia
Nov 13, 2010·Pediatric Blood & Cancer·Kelsey A JohnsonRochelle Bagatell
Mar 15, 2013·Pediatric Hematology and Oncology·E Susan Amirian
Sep 12, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Kyung Im KimJung Mi Oh
Mar 18, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Daihong LiuQian Jiang
Jul 22, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Alexander DewKoen van Besien
Feb 1, 2014·The Lancet Oncology·Patricia C ValeryFreddie Bray
Apr 15, 2015·Toxicology and Applied Pharmacology·Daniel J ConklinAruni Bhatnagar
Oct 22, 2014·Journal of Pediatric Hematology/oncology·Julia DiLabioAngela Punnett
Nov 20, 2016·American Journal of Hematology·Lena E WinestoneRichard Aplenc
Mar 8, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Monika L MetzgerScott C Howard
Oct 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Della L HowellWilliam G Woods
Mar 8, 2017·Pediatric Blood & Cancer·M Monica GramatgesKaren R Rabin

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.